(WO/2009/093972) ENANTIOMERICALLY PURE (-) 2-[1-(7-METHYL-2-(MORPHOLIN-4-YL)-4-OXO-4<i>H</i>-PYRIDO[1,2-<i>A</i>]PYRIMIDIN-9-YL)ETHYLAMINO]BENZOIC ACID, ITS USE IN MEDICAL THERAPY, AND A PHARMACEUTICAL COMPOSITION COMPRISING IT - 026

(WO/2009/093972) ENANTIOMERICALLY PURE (-) 2-[1-(7-METHYL-2-(MORPHOLIN-4-YL)-4-OXO-4H-PYRIDO[1,2-A]PYRIMIDIN-9-YL)ETHYLAMINO]BENZOIC ACID, ITS USE IN MEDICAL THERAPY, AND A PHARMACEUTICAL COMPOSITION COMPRISING IT - 026

Latest bibliographic data on file with the International Bureau
Pub. No.:  WO/2009/093972   International Application No.:  PCT/SE2009/050065
Publication Date:30.07.2009 International Filing Date:22.01.2009
IPC: C07D 471/04 (2006.01), A61K 31/519 (2006.01), A61K 31/5377 (2006.01), A61P 11/00 (2006.01), A61P 35/00 (2006.01), A61P 7/02 (2006.01), A61P 9/10 (2006.01)
Applicants:ASTRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE) (All Except US).
FJELLSTRÖM, Ola [SE/SE]; (SE) (US Only).
GUSTAFSSON, David [SE/SE]; (SE) (US Only).
JACKSON, Shaun [AU/AU]; (AU) (US Only).
LINDBERG, Jan Å [SE/SE]; (SE) (US Only).
Inventors:FJELLSTRÖM, Ola; (SE).
GUSTAFSSON, David; (SE).
JACKSON, Shaun; (AU).
LINDBERG, Jan Å; (SE).
Agent:ASTRAZENECA AB; AstraZeneca Intellectual Property S-151 85 Södertälje (SE).
Priority Data:
61/023,498 25.01.2008 US
Title: ENANTIOMERICALLY PURE (-) 2-[1-(7-METHYL-2-(MORPHOLIN-4-YL)-4-OXO-4H-PYRIDO[1,2-A]PYRIMIDIN-9-YL)ETHYLAMINO]BENZOIC ACID, ITS USE IN MEDICAL THERAPY, AND A PHARMACEUTICAL COMPOSITION COMPRISING IT - 026
Abstract: The present invention relates to enantiomerically pure (-) 2-[1-(7-methyl-2-(morpholin-4-yl)-4-oxo-4H-pyrido[1,2-a]pyrimidin-9- yl)ethylamino]benzoic acid or pharmaceutically acceptable salts thereof, it being in a solid state, its use in medical therapy, pharmaceutical composition comprising it, its use in the preparation of a medicament for use in a method for preventing or treating diseases, and its use in method for preventing or treating disease. The present invention relates to a selective inhibitor of phosphoinositide (PI) 3-kinase β and use of the selective inhibitor in e.g. anti-thrombotic therapy.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Org. (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (EAPO) (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (OAPI) (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language:English (EN)
Filing Language:English (EN)

PATENTSCOPE®

Related Links

E-Newsletters